It was January 24, 2020 that BioNTech CEO Uğur Shahin learned that Covid-19 could become a pandemic.
It took more than a month and a half for the World Health Organization to officially declare a pandemic, but Sahin met with the wife of BioNTech co-founder and chief medical officer Özlem Türeci. Together, they agreed to direct most of the company’s resources to vaccine development.
“He approached me and explained his thoughts and his fears,” Turesi said. “And it soon became clear to both of us that the technology we had and had already clinically developed could help ensure a quick response.”
Until that time, BioNTech was primarily focused on developing new cancer treatments. The company was little known internationally. However, the founders were confident in the potential of their mRNA technology, which they knew could provoke a strong immune response. BioNTech knew that a larger partner was needed to successfully manufacture, test, and manufacture the Covid vaccine on a global scale. The company is already associated with Pfizer and has been working with Pfizer since 2018 to develop an mRNA-based influenza vaccine, which is in clinical trials. So BioNTech turned to them.
The company was successful. In August, the Pfizer-BioNTech vaccine was first fully approved by the FDA.
Watch the video to learn about the rise of BioNTech.
How BioNTech moved from the lesser-known to the creation of the Covid vaccine
Source link How BioNTech moved from the lesser-known to the creation of the Covid vaccine